The role of selected matrix metalloproteinases and their inhibitors in colorectal cancer development;Rola wybranych metaloproteinaz i ich inhibitorów w rozwoju raka jelita grubego

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 64, Issue , 2010, Pages 22-30

  Groblewska, Magdalena ^a   Mroczko, Barbara ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Colorectal adenoma; Colorectal cancer; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

BIOSYNTHESIS; CANCER INVASION; CANCER STAGING; COLORECTAL TUMOR; HUMAN; METABOLISM; MORTALITY; PATHOLOGY; REVIEW;

COLORECTAL NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 77950399682     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Baker E. A., Leaper D. J.: Measuring gelatinase activity in colorectal cancer. Eur. J. Surg. Oncol., 2002;28:24-29 (Pubitemid 41122778)
2. Blavier L., Henriet P., Imren S., Declerck Y. A.: Tissue inhibitors of matrix metalloproteinases in cancer. Ann. NY Acad. Sci., 1999;878:108-119 (Pubitemid 29353563)
3. Bogaczewicz J., Chodorowska G., Krasowska D.: Rola metaloproteinaz macierzy i tkankowych inhibitorów metaloproteinaz w układzie odpornościowym skóry. Przegl. Dermatol., 2005;92:139-149
4. Bogaczewicz J., Dudek W., Wroński J., Chodorowska G., Przywara S., Krasowska D., Zubilewicz T.: Rolametaloproteinaz macierzy wpowstawaniu owrzodzeń ż ylnych goleni. Pol. Merk. Lek., 2005;19:686-692
5. Boudreau N., Sympson C. J., Werb Z., Bissell M. J.: Suppression of ice and apoptosis in mammary epithelial-cells by extracellular-matrix. Science, 1995;267:891-893
6. Cawston T. E., Mercer E.: Preferential binding of collagenase to a2-macroglobulin in the presence of the tissue inhibitor of metalloproteinases. FEBS Lett., 1986;209:9-12 (Pubitemid 17224565)
7. Daniel P., Wagrowska-Danilewicz M., Danilewicz M., Stasikowska O., Malecka-Panas E.: Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma. Int. J. Colorectal. Dis., 2007;22:1165-1172 (Pubitemid 47304784)
8. Egeblad M., Werb Z.: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002;2:161-174 (Pubitemid 37328786)
9. Fearon E. R., Vogelstein B.: A genetic model for colorectal tumorigenesis. Cell, 1990;61:759-767
10. Gallegos N. C., Smales C., Savage F. J., Hembry R. M., Boulos P. B.: The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg. Oncol., 1995;4:21-29
11. Greene J., Wang M., Liu Y. E., Raymond L. A., Rosen C., Shi Y. E.: Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem., 1996;271:30375-30380 (Pubitemid 26404039)
12. Guedez L., Courtenmanch L., Stetler-Stevensoon M.: Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood, 1998;92:1342-1349 (Pubitemid 28369048)
13. Guzińska-Ustymowicz K.: MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res., 2006;26:1589-1594
14. Hayakawa T., Yamashita K., Ohuchi E., Shinagawa A.: Cell growthpromoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell. Sci., 1994;107:2373-2379 (Pubitemid 24292486)
15. Herszényi L., Sipos F., Galamb O., Solymosi N., Hritz I., Miheller P., Berczi L., Molnár B., Tulassay Z.: Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon. Pathol. Oncol. Res., 2008;14:31-37
16. Heslin M. J., Yan J., Johnson M. R., Weiss H., Diasio R. B., Urist M. M.: Role of matrix metalloproteinases in colorectal carcinogenesis. Ann. Surg., 2001;233:786-792 (Pubitemid 32494559)
17. Hewitt R. E., Brown K. E., Corcoran M., Stetler-Stevenson W. G.: Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP-1) in a more tumourigenic colon cancer cell line. J. Pathol., 2000;192:455-459
18. Holten-Andersen M. N., Stephens R. W., Nielsen H. J., Murphy G., Christensen I. J., Stetler-Stevenson W., Brünner N.: High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin. Cancer Res. 2000;6:4292-4299
19. Hurst N. G., Stocken D. D., Wilson S., Keh C., Wakelam M. J., Ismail T.: Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br. J. Cancer, 2007;97:971-977 (Pubitemid 47519304)
20. Illemann M., Bird N., Majeed A., Sehested M., Laerum O. D., Lund L. R., Danø K., Nielsen B. S.: MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol. Cancer Res., 2006;4:293-302 (Pubitemid 43837330)
21. Ishida H., Murata N., Hayashi Y., Tada M., Hashimoto D.: Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg. Today, 2003;33:885-892 (Pubitemid 38037345)
22. Islekel H., Oktay G., Terzi C., Canda A. E., Füzün M., Küpelioglu A.: Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell. Biochem. Funct., 2007;25:433-441 (Pubitemid 47066721)
23. Jass J. R., Sobin L. H.: WHO international histological classification of tumors. histological typing of intestinal tumors. New York, Springer-Verlag 1989
24. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J.: Cancer statistics, 2009. CA Cancer J. Clin., 2009;59:225-249
25. Jinga D. C., Blidaru A., Condrea I., Ardeleanu C., Dragomir C., Szegli G., Stefanescu M., Matache C.: MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J. Cell. Mol. Med., 2006;10:499-510 (Pubitemid 44872701)
26. Kim T. D., Song K. S., Li G., Choi H., Park H. D., Lim K., Hwang B. D., Yoon W. H.: Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer, 2006;6:211
27. Kołomecki K.: Hamowanie funkcji metaloproteinaz - możliwości zastosowania klinicznego. Onkol. Pol., 2000;3:163-167
28. Lambert E., Dasse E., Haye B., Petitfrere E.: TIMPs as multifacial proteins. Crit. Rev. Oncol. Hematol., 2004;49:187-198 (Pubitemid 38251351)
29. Leco K. J., Apte S. S., Taniguchi G. T., Hawkes S. P., Khokha R., Schultz G. A., Edwards D. R.: Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett., 1997;401:213-217 (Pubitemid 27056118)
30. Lein M., Nowak L., Jung K., Laube C., Ulbricht N., Schnorr D., Loening S. A.: Metalloproteinases: and tissue inhibitors of matrixmetalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue. Ann. NY Acad. Sci., 1999;878:544-546 (Pubitemid 29353608)
31. Lubbe W. J., Zhou Z. Y., Fu W., Zuzga D., Schulz S., Fridman R., Muschel R. J., Waldman S. A., Pitari G. M.: Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin. Cancer Res., 2006;12:1876-1882
32. Luparello C., Avanzato G., Carella C., Pucci-Minafra I.: Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res. Treat., 1999;54:235-244 (Pubitemid 29322346)
33. McCarthy K., Maguire T., McGreal G., McDermott E., O'Higgins N., Duffy M. J.: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int. J. Cancer 1999;84:44-48 (Pubitemid 29059107)
34. Murashige M., Miyahara M., Shiraishi N., Saito T., Kohno K., Kobayashi M.: Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn. J. Clin. Oncol., 1996;26:303-309 (Pubitemid 126470688)
35. Murphy F. R., Issa R., Zhou X. Y., Ratnarajah S., Nagase H., Arthur M. J., Benyon C., Iredale J. P.: Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem., 2002;277:11069-11076 (Pubitemid 34952866)
36. Murphy G., Houbrechts A., Cockett M. I., Wiliamson R. A., O'Shea M., Docherty A. J.: The treminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry, 1991;30:8097-8102
37. Murray D., Morrin M., McDonnell S.: Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res., 2004;24:489-494 (Pubitemid 38623124)
38. Nagase H., Woessner J. F. Jr.: Matrix metalloproteinases. J. Biol. Chem., 1999;274:21491-21494
39. Nebeshima K., Inoue T., Shimao Y., Sameshima T.: Matrix metalloproteinases in tumor invassion: Role for cell migration. Pathol. Int., 2002;52:255-264 (Pubitemid 34587810)
40. Nowacki M. P.: Rak jelita grubego, W.: Onkologia kliniczna. Red. Krzakowski M. T. II. Wyd. Med. Borgis, Warszawa, 2001;237-253
41. Oberg A., Hoythya M., Tavelin B., Stenling R., Lindmark G.: Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res., 2000;20:1085-1091 (Pubitemid 30240680)
42. Scott N., Quirke P.: Molecular biology of colorectal neoplasia. Gut 1993;34:289-292 (Pubitemid 23080248)
43. Sinnamon M. J., Carter K. J., Fingleton B., Matrisian L. M.: Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse. Int. J. Exp. Pathol., 2008;89:466-475
44. Sutnar A., Pesta M., Liska V., Treska V., Skalicky T., Kormunda S., Topolcan O., Cerny R., Holubec L. Jr.: Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases. Tumour Biol., 2007;28:247-252 (Pubitemid 350165830)
45. Tomita T., Iwata K.: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis. Colon Rectum, 1996;39:1255-1264 (Pubitemid 26389536)
46. Torii A., Kodera Y., Uesaka K., Hirai T., Yasui K., Morimoto T., Yamamura Y., Kato T., Hayakawa T., Fujimoto N., Kito T.: Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br. J. Surg., 1997;84:133-136 (Pubitemid 27033129)
47. Unsal D., Akyurek N., Uner A., Erpolat O. P., Han U., Akmansu M., Mentes B. B., Dursun A.: Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Am. J. Clin. Oncol., 2008;31:55-63
48. Unsal Kilic D., Uner A., Akyurek N., Erpolat P., Dursun A., Pak Y.: Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2007;67:196-203 (Pubitemid 44959478)
49. Vihinen P., Kahari V. M.: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer, 2002;99:157-166 (Pubitemid 34309470)
50. Waas E. T., Hendriks T., Lomme R. M., Wobbes T.: Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis. Colon Rectum, 2005;48:700-710 (Pubitemid 40880716)
51. Wang T., Yamashita K., Iwata K., Hayakawa T.: Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways. Biochem. Biophys. Res. Commun., 2002;296:201-205 (Pubitemid 35002079)
52. Werb Z., Ashkenas J., MacAuley A., Wiesen J. F.: Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Braz. J. Med. Biol. Res., 1996;29:1087-1097 (Pubitemid 126479686)
53. Wilhelm S. M., Collier I. E., Marmer B. L., Eisen A. Z., Grant G. A., Goldberg G. I.: SV40-transformed human lung fibroblasts secrete a 92-κDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem., 1989;264:17213-17221 (Pubitemid 19255553)
54. Woessner J. F. Jr.: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J., 1991;5:2145-2154 (Pubitemid 21905847)
55. Wojtowicz-Praga S., Dickson R. B., Hawkins M. J.: Matrix metalloproteinase inhibitors. Invest. New Drugs., 1997;15:61-75 (Pubitemid 27217752)
56. Wu W., He J. T., Ruan J. D., Wang R. B., Zhang Y. D.: Expression of MMP-2, MMP-9 and collagen type IV and their relationship in colorectal carcinomas. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi., 2008;24:908-909
57. Yamashita K., Suzuki M., Iwata H., Koike T., Hamaguchi M., Shinagawa A., Noguchi T., Hayakawa T.: Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett., 1996;396:103-107 (Pubitemid 26360290)
58. Ylisirnio S., Hoyhtya M., Turpeenniemi-Hujanen T.: Serum matrix metalloproteinases-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer-TIMP-1 as prognostic marker. Anticancer Res., 2000;20:1311-1316 (Pubitemid 30240720)
59. Yukawa N., Yoshikawa T., Akaike M., Sugimasa Y., Rino Y., Masuda M., Imada T.: Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology 2007;72:205-208 (Pubitemid 351161611)
60. Yukawa N., Yoshikawa T., Akaike M., Sugimasa Y., Takemiya S., Yanoma S., Imada T., Noguchi Y.: Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer. Anticancer Res. 2004;24:2101-2105 (Pubitemid 38954641)
61. Zeng Z. S., Cohen A. M., Guillem J. G.: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis, 1999;20:749-755 (Pubitemid 29191855)